4.7 Article

Prognostic alternative mRNA splicing signature in non-small cell lung cancer

期刊

CANCER LETTERS
卷 393, 期 -, 页码 40-51

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.02.016

关键词

Alternative splicing; NSCLC; Exon skip; Survival; Prognosis

类别

资金

  1. National Key Basic Research Development Plan 973 Plan [2014CB542006]
  2. CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001]
  3. International Science and Technology Corporation and Exchange Project [2015DFA31090]

向作者/读者索取更多资源

Alternative splicing provides a major mechanism to generate protein diversity. Increasing evidence suggests a link of dysregulation of splicing associated with cancer. Genome-wide alternative splicing profiling in lung cancer remains largely unstudied. We generated alternative splicing profiles in 491 lung adenocarcinoma (WAD) and 471 lung squamous cell carcinoma (LUSC) patients in TCGA using RNA-seq data, prognostic models and splicing networks were built by integrated bioinformatics analysis. A total of 3691 and 2403 alternative splicing events were significantly associated with patient survival in LUAD and LUSC, respectively, including EGFR, CD44, PIK3C3, RRAS2, MAPKAPI and FGFR2. The area under the curve of the receiver-operator characteristic curve for prognostic predictor in NSCLC was 0.817 at 2000 days of overall survival which were also over 0.8 in LUAD and LUSC, separately. Interestingly, splicing correlation networks uncovered opposite roles of splicing factors in LUAD and LUSC. We created prognostic predictors based on alternative splicing events with high performances for risk stratification in NSCLC patients and uncovered interesting splicing networks in LUAD and LUSC which could be underlying mechanisms. (C) 2017 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据